SHL to feature Molly® 2.25 and Molly® C at the 2016 Pharmapack Europe

Pharmapack Image 800x480

At this year’s Pharmapack Europe held at Paris Expo, Porte de Versailles in Paris, SHL will be featuring Molly® 2.25, the much talked-about high volume autoinjector, as well as Molly® C, a newly developed product related to connectivity.

The Molly® 2.25 is SHL’s first high volume autoinjector with its design based on the original 1ml Molly®; it was created to meet the increasing need for simple delivery of larger doses. With improved features, the preconfigured device will be extremely attractive to customers who are looking for top-quality products with quick development timelines and reduced costs.

Derived from SHL’s connectivity-based program—Alubena™—for drug delivery, the Molly® C is a disposable autoinjector with a reusable recording unit, which tracks and saves injection data. This concept was created to improve patient adherence, which has long been a problem in the healthcare industry. With Molly® “C”, which stands for “connected device”, injection data can be better managed and stored with an app that is available for demonstration at the SHL booth.

These two new products are indications that SHL is constantly keeping a focused and innovative approach to advanced drug delivery, developing products that reflect market needs.

Both Molly® 2.25 and Molly® C will be available for demonstration at the SHL booth in the upcoming Pharmapack event. For further details, please visit us at Booth 736, Hall 5.2.

About SHL

SHL Group is a world-leading solutions provider in the design, development, and manufacturing of advanced drug delivery devices such as autoinjectors, pen injectors and advanced inhaler systems. We also offer core competencies and services in the fields of medtech and patient care solutions. With locations in Taiwan, Switzerland, Sweden, China and the US, our experienced engineers and designers develop product enhancements as well as breakthrough drug delivery and patient care solutions for pharma and biotech clients globally. Significant investment in R&D has enhanced our broad pipeline of next-generation drug delivery systems that support ongoing innovations in drug development and digital healthcare. This includes advanced reusable and disposable injectors that can accommodate high volume and high viscosities and can be enhanced through digital implementations.

With over 4,800 employees worldwide, SHL Group consists of several distinct group companies:

SHL Medical designs, develops and manufactures advanced drug delivery devices, as well as provides final assembly, labeling and packaging services for leading pharmaceutical and biotech companies across the globe.

SHL Healthcare develops and manufactures equipment solutions for home, hospital and long term care use.

SHL Technologies provides contract manufacturing and engineering services for the production of complex medtech and industrial products.

For additional information, visit

Media contact:


Related News